Apyx Medical Corporation
APYX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APYX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APYX
Apyx Medical Corporation is a medical technology company that develops and commercializes helium plasma technology for surgical and aesthetic applications, including its AYON product launched in September 2025.
Key risk: High debt leverage
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Apyx Medical Corporation.
Apyx Medical Corporation is a medical technology company that develops and commercializes helium plasma technology for surgical and aesthetic applications, including its AYON product launched in September 2025.
- Cash & equivalents of $27.6M as of 2026-06-30 [sec].
- Total revenue of $13.9M for the quarter ended 2026-06-30 [sec].
- Net loss of $3.2M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $14.5M and total debt of $37.5M as of 2026-06-30 [sec].
- Launched AYON in September 2025 [sec_mda · as of 2026-03-10].
What works
- The company has a portfolio of 41 U.S. patents and 61 foreign patents to protect its proprietary technology [sec_mda · as of 2026-03-10].
- Net cash used in operating activities decreased to $5.5M for the nine months ended September 30, 2025, from $15.5M in the prior-year period, reflecting cost-cutting measures [sec_mda · as of 2025-11-06].
- The company has established relationships with key plastic surgeons and cosmetic physicians to support commercialization and product development [sec_mda · as of 2026-03-10].
What to weigh
- The company has a net loss of $3.2M for the quarter ended 2026-06-30 and an accumulated deficit, indicating ongoing unprofitability [sec].
- Total debt of $37.5M exceeds shareholders' equity of $14.5M as of 2026-06-30, reflecting a leveraged balance sheet [sec].
- Commercialization of new products like AYON faces risks including regulatory clearance, market acceptance, and competition in a rapidly innovating aesthetic equipment market [sec_mda · as of 2026-03-10].
- The company may need additional financing, which could cause dilution or restrictive debt covenants, and cannot guarantee availability on acceptable terms [sec_mda · as of 2025-11-06].
From the filings
Quoted directly from source documents.
Risks & what to watch (4)›
Key risks
- High debt leverage — Total debt of $37.5M exceeds equity of $14.5M as of 2026-06-30, increasing financial risk [sec].
- Commercialization uncertainty — New product AYON may not gain market acceptance, and commercialization depends on regulatory and market factors [sec_mda · as of 2026-03-10].
- Need for additional capital — The company may require financing, which could dilute shareholders or impose restrictive covenants [sec_mda · as of 2025-11-06].
- Rapid technological change — The aesthetic equipment market requires continuous innovation; failure to keep pace could harm competitive position [sec_mda · as of 2026-03-10].
What to watch
- Adoption and revenue contribution of the AYON product launched in September 2025 [sec_mda · as of 2026-03-10].
- Ability to reduce net losses and achieve profitability, given the $3.2M net loss in Q2 2026 [sec].
- Debt management and refinancing efforts, with total debt of $37.5M as of 2026-06-30 [sec].
- Future financing activities, as the company may need additional capital to fund operations [sec_mda · as of 2025-11-06].
Sources: Catalysts · SEC MD&A · Generated August 21, 2026 · How we verify sources →
Run Apyx Medical Corporation through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apyx Medical Corporation facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
30.3 months
D/E 4.69
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 0.6%
- Days to cover
- 2.0
- Shares short
- 221,167
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APYX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Apyx Medical Corporation?
Apyx Medical Corporation is a medical technology company that develops and commercializes helium plasma technology for surgical and aesthetic applications, including its AYON product launched in September 2025.
What is Apyx Medical Corporation's lead drug candidate?
Apyx Medical Corporation's most advanced tracked candidate is renuvion (Approved) for Dermal resurfacing for moderate to severe wrinkles and rhytides (Fitzpatrick Skin Types I, II or III).
Who is the CEO of Apyx Medical Corporation?
Mr. Charles D. Goodwin II is the chief executive officer of Apyx Medical Corporation (APYX).
Where is Apyx Medical Corporation headquartered?
Apyx Medical Corporation (APYX) is headquartered in Clearwater, FL, United States.
What therapeutic areas does Apyx Medical Corporation focus on?
Apyx Medical Corporation develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.